Stephen I-Hong Hsu, MD, PhD
Chief Executive Officer
Chief Scientific Officer
Prometheon Pharma, LLC
Sid Martin Biotechnology Incubator
University of Florida
10285 Research Drive
Alachua, FL 32615, USA
Dr. Hsu is the Founder, CEO and Chief Scientific Officer of Prometheon Pharma, LLC, a resident company of the Sid Martin Biotechnology Incubator (named #1 incubator in the world, 2013) of the University of Florida. Dr. Hsus international academic career as a clinician-scientist and administrator of multiple clinical and graduate training programs spans more than three decades. He received a combined MD-PhD degree in Molecular Pharmacology as a Scholar of the NIH Medical Scientist Training Program at the Albert Einstein College of Medicine. His studies on the molecular genetics of the mdr (P-glycoprotein) genes were done in the laboratory of Susan Horwitz, whose group identified the mechanism of action of bleomycin and taxol. He completed his Internal Medicine Residency and Nephrology Fellowship Training at the Massachusetts General Hospital, during which he co-edited the first textbook of evidence-based medicine. He held his first academic appointments at the Yong Loo Lin School of Medicine (National University of Singapore) and the Genome Institute of Singapore (Biopolis), where he developed research programs in the molecular genetics of kidney diseases and prostate cancer. As the Director of Research for the National Kidney Foundation of Singapore, he developed a disease prevention program and expanded his expertise to population-based and genetic epidemiology through the development of a nationwide screening program for the detection of early disease. He also continued to practice clinical nephrology during the SARS epidemic in Singapore at the National University Hospital where he held the distinction of being the youngest member in the history of the hospitals Medical Board. In 2005 he was recruited to the Renal Unit of the Brigham and Womens Hospital (Harvard Medical School). In 2007, he was recruited to be the first occupant of the R. Glenn Davis (DCI) Endowed Chair in Clinical and Translational Medicine, and the Director of the MD-PhD Training Program at the University of Florida College of Medicine where he held joint appointments in the Departments of Medicine and Molecular Genetics and Microbiology. He is the first recipient of an inaugural award for Innovations in Research Training and Education by the American Association of Medical Colleges. He was named a Scholar of the Clinical Translational Science Institute at the University of Florida in 2009.
Dr. Hsu is the Chief Scientific Officer for Prometheon Pharma, LLC, setting the direction for their research and development efforts in a proprietary transdermal patch platform technology for peptide/protein drug delivery. He also leads a research team in further determining the basis for resistance to diet-induced obesity in a TRIP-Br2 knockout mouse model he developed (Nature Medicine, January 2013). This effort is the basis for a drug discovery and development program aimed at identifying lead compounds for novel classes of anti-obesity and anti-cachexia drugs.
• (1992) Alpha Omega Alpha Medical Honor Society
• (1992) Up John Achievement Award for outstanding achievement in molecular pharmacology research
• (1992) Award for distinguished performance in research (1st Prize), The Associated Medical Schools of New York
• (1999) Best Basic Science Poster Award, 3rd NUH Faculty of Medicine Annual Scientific Meeting
• (2000) The Pharos Editors Prize for the essay On Being a Scientist
• (2001) Royal Society of Medicine Library Prize (2001) for textbook Evidence-Based On Call: Acute Medicine. Editors S. Straus, S.I.-H. Hsu,C.M. Ball, R.S. Phillips, Harcourt-Brace, UK
• (2002) Singapore Biomedical Research Council Young Investigator Award
• (2003) Merit Award, Basic Science Poster Contest, 4th Combined Scientific Meeting (Life Sciences in Singapore: Integrating Multidimensional Perspectives)
• (2003) Blue Ribbon Poster Award, World Congress of Nephrology, Germany
• (2004) Best Clinical Science Poster Award Finalist, NUS-NUH annual scientific meeting, Singapore
• (2004) Doctor Award Finalist, National Healthcare Group Annual Scientific Congress, Singapore
• (2005) National Kidney Foundation Clinician-Scientist Award, USA
• (2005) American Society of Nephrology Gottschalk Award, USA
• (2009) Clinical Translational Science Institute Scholar Award, University of Florida, Gainesville, FL
• (2010) Excellence in Teaching Award, Department of Medicine, University of Florida, Gainesville, FL
• (2010) Donald Etzweiler Visiting Scholar, International Diabetes Center, Minneapolis, MN
• (2011) Semi-Finalist (Sweet Sixteen), 2nd Annual Cade Museum Prize for Innovation Award (USA)
• (2012) Finalist (Final Four), 3rd Annual Cade Museum Prize for Innovation Award (USA)
• (2012) Inaugural Award for Innovations in Research Training and Education (American Association of Medical Colleges, USA)
• (2014) Grand Prize, MIT-CHIEF Business Plan Competition from among 200+ applicants worldwide (Massachusetts Institute of Technology, Boston, MA)
PROFESSIONAL SOCIETY MEMBERSHIPS
• (1990-Present) American Medical Association
• (1995-Present) American Society of Nephrology
• (1995-Present) International Society of Nephrology
• (2000-Present) American Heart Association High Blood Pressure Research Council
• (2000-Present) American Heart Association Council on Kidney in Cardiovascular Disease
• (2000-Present) American Heart Association Kidney Council, Member
• (2002-Present) American Association for the Advancement of Science, Invited Member
• (2005-Present) American College of Physicians
• (2008-Present) Florida Medical Association
• (2008-Present) Florida Society of Nephrology
• (2009-Present) American Association for Cancer Research
• (2009-Present) International Human Papillomavirus Society
• (2009-Present) Society of Clinical and Translational Science
• (2010-Present) Kidney & Urology Foundation of America
• (2010-Present) United Mitochondrial Disease Foundation
• (2010-Present) American Society for Biochemistry and Molecular Biology
• (2011-Present) American Physician Scientist Association
• (2012-Present) American Diabetes Association
• (2014-present) European Society for Paediatric Endocrinology
PUBLICATIONS (PEER REVIEWED PAPERS)
1. Hsu, SIH, Lothstein L, Horwitz SB. Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. J Biol Chem. 1989; 264: 12053-12062.
2. Lothstein L, Hsu SIH, Horwitz SB, Greenberger LM. Alternate overexpression of two P-glycoprotein genes is associated with changes in multidrug resistance in a J774.2 cell line. J Biol Chem. 1989; 264: 16054-16058.
3. Hsu, SIH, Cohen D, Kirschner L, Lothstein L, Hartstein M. Horwitz SB. Structural analysis of the mouse mdr1a(P-glycoprotein) promoter reveals the basis for differential transcript heterogeneity in multli drug-resistant J774. 2 cells. Mol Cell Biol. 1990; 10: 3596-3606. doi:10.1128/MCB.10.7.3596
4. Yang CPH, Cohen D, Greenberger LM, Hsu SIH, Horwitz SB. Differential transport properties of two mdr gene products are distinguished by progesterone. J Biol Chem. 1990; 265: 10282-10288.
5. Cohen D, Piekarz RL, Hsu SIH, DePinho RA, Carrasco N, Horwitz SB. Structural and functional analysis of the mouse mdr1b gene promoter. J Biol Chem. 1991; 266: 2239-2244.
6. Cohen D, Higman SM, Hsu SIH, Horwitz SB. The involvement of a LINE-1 element in a DNA arrangement upstream of the mdr1a gene in a taxol multi-drug resistant murine cell line. J Biol Chem. 1992; 267: 20248-20254.
7. Kirschner LS, Greenberger LM, Hsu SIH, et al. Biochemical and genetic characterization of the multidrug resistance phenotype in murine macrophage-like J774.2 cells. Biochem Pharmacol. 1992; 43: 77-87. doi:10.1016/0006-2952(92)90664-5
8. Hsu SIH, Thadhani RI, Daniels GH. Acute compartment syndrome in a hypothyroid patient. Thyroid. 1995; 5: 305-308. doi:10.1089/thy.1995.5.305
9. Hsu SIH. Somatization among Asian immigrants and refugees as a culturally-shaped illness behavior. Annals Acad Med Singapore. 1999; 28: 841-845.
10. Hsu SIH. On being a scientist. Pharos Alpha Omega Alpha Honor Med Soc. 2000; 63: 11-13.
11. Hsu SIH, Ramirez SB, Winn MP, Bonventre JV, Owen WF. Evidence for genetic factors in the development and progression of IgA nephropathy. Kidney Int. 2000; 57: 1818-1835. doi:10.1046/j.1523-1755.2000.00032.x
12. Lim YK, Jenner A, Bin Ali A, et al. Haptoglobin reduces renal oxidative DNA and tissue damage during phenyl hydrazine-induced hemolysis. Kidney Int. 2000; 58: 1033-1044. doi:10.1046/j.1523-1755.2000.00261.x
13. Hsu SIH. The molecular pathogenesis and experimental therapy of IgA nephropathy: recent advances and future prospects. Curr Mol Med. 2001; 1: 183-196.
14. Hsu SIH, Yang CM, Sim KG, Hentschel DM, O Leary E, Bonventre JV. TRIP-Br: a novel family of PHD zinc finger and bromodomain interacting proteins that regulate the transcriptional activity of E2F-1/DP-1. EMBO J. 2001; 20: 2273-2285. doi: 10.1093/emboj/20.9.2273
15. Ramirez SPB, Hsu SIH, Nandakumar M, Friedman EA, Durai TT, Owen WF. Funding ESRD care through charity: the paradigm of the National Kidney Foundation of Singapore. Semin Nephrol. 2001; 21: 411-418.
16. Mazze RS, Simonson G, Strock E, et al. Staged diabetes management: a systematic evidence-based approach to the prevention and treatment of diabetes and its co-morbidities. Pract Diab Int. 2001; 18: S1-S16. doi:10.1002/pdi.240
17. Hsu SIH. Biopsy-proven acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin therapy. Pharmacotherapy. 2001; 21: 1233-1239. doi:10.1592/phco.21.15.1233.33901
18. Ramirez SPB, Hsu SIH, McClellan W. Low body weight is a risk factor for proteinuria in a multi-ethnic Southeast Asian pediatric population. Am J Kid Dis. 2001; 38: 1045-1054.
19. Ramirez SPB, McClellan W, Port FK, Hsu SIH. Risk factors for proteinuria among a large, multiracial, Southeast Asian population. J Am Soc Nephrol. 2002; 13: 1907-1917. doi:10.1097/01.ASN.0000018406.20282.C8
20. Ramirez SPB, Hsu SIH, McClellan W. Taking a public health approach to the prevention of end-stage renal disease: The NKF Singapore Program. Kidney Int Suppl. 83: S61-S65.
21. Ramirez SPB, Durai TT, Hsu SIH. Paradigms of public-private partnerships in end-stage renal disease care: The National Kidney Foundation Singapore. Kidney Int. 2003; Suppl(83): S101-S107.
22. Hsu, SIH, Couser WG. Chronic Progression of Tubulointerstitial Damage in Proteinuric Renal Disease is Mediated by Complement Activation: A Therapeutic Role for Complement Inhibitors? J Am Soc Nephrol. 2003; Suppl(2): S186-S191. doi: 10.1097/01.ASN.0000070032.58017.20
23. Gupta S, Takhar SPP, Degenkolbe R, et al. The Human Papillomavirus Type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. Virology. 2003; 317: 155-164. doi: 10.1016/j.virol.2003.08.008
24. Thio SSC, Bonventre JV, Hsu SIH. The CtBP2 co-repressor is regulated by NADH-dependent dimerization and possesses a novel N-terminal repression domain. Nucleic Acids Res. 2004; 32: 1836-1847. doi:10.1093/nar/gkh344
25. Qiu LQ, Sinniah R, Hsu SIH. Down-regulation of Bcl-2 by podocytes is associated with progressive glomerular injuries and clinical indices of poor renal outcome in human IgA nephritis. J Am Soc Nephrol. 2004; 15: 79-90. doi:10.1097/01.ASN.0000104573.54132.2E
26. Qiu LQ, Sinniah R, Hsu SIH. Role of differential and cell type-specific expression of cell cycle regulatory proteins in mediating progressive glomerular injury in human IgA nephropathy. Lab Invest. 2004; 84: 1112-1125. doi:10.1038/labinvest.3700144
27. Qiu LQ, Sinniah, R, Hsu SIH. Coupled induction of iNOS and p53 up-regulation in renal resident cells may be linked with apoptotic activity in the pathogenesis of progressive IgAN. J Am Soc Nephrol. 2004; 15: 2066-2078. doi:10.1097/01.ASN.0000133532.99109.3D
28. Sim KG, Zang Z, Yang MC, Bonventre JV, Hsu SIH. TRIP-Br links E2F to novel functions in the regulation of cyclin E expression during cell cycle progression and in the maintenance of genomic stability. Cell Cycle. 2004; 3: 1296-1303. doi:10.4161/cc.3.10.1157
29. Hsu SIH. Diseases of the kidney: Molecular mechanisms and current therapy. Curr Mol Med. 2005; 5: 454.
30. Vidal BC Jr, Bonventre JV, Hsu, SIH. Towards the application of proteomics in renal disease diagnosis. Clin Science. 2005; 109: 421-430. doi:10.1042/CS20050085
31. Zheng L, Sinniah R, Hsu SIH. In situ glomerular expression of activated NF-B in human lupus nephritis and other proteinuric glomerulonephritides. Virch Arch. 2005; 448: 172-183. doi:10.1007/s00428-005-0061-9
32. Zheng L, Sinniah, R, Hsu SIH. The role of NF-kB activation in tubulointerstitial lesions in lupus nephritis. Hum Pathol. 2006; 7: 637-647.
33. Sim KG, Cheong JK, Hsu SIH. The TRIP-Br family of transcriptional regulators is essential for the execution of cyclin E-mediated cell cycle progression. Cell Cycle. 2006; 5: 1111-1115. doi:10.4161/cc.5.10.2797
34. Soo RA, Wu J, Aggarwal A, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Annals Oncol. 2006; 17: 1625-1630.
35. Zang ZZ, Sim KG, Cheong JK, Yang CM, Yap CS, Hsu SIH. Exploiting the TRIP-Br family of cell cycle regulatory proteins as chemotherapeutic drug targets in human cancer. Cancer Biol Ther. 2007; 6: 712-718. doi:10.4161/cbt.6.5.3964
36. Zheng L, Sinniah R, Hsu SIH. Pathogenic role of NF-kB activation in tubulointerstitial inflammatory lesions in human lupus nephritis. J Histochem Cytochem. 2008; 56: 517-529. doi:10.1369/jhc.7A7368.2008
37. Cheong JK, Gunaratnam L, Hsu SIH. CRM1-mediated nuclear export is required for 26 S proteasome-dependent degradation of the TRIP-Br2 proto-oncoprotein. J. Biol Chem. 2008; 283: 1161-11676. doi:10.1074/jbc.M708365200
38. Zang ZZ, Gunaratnam L, Cheong JK, et al. Identification of PP2A as a novel interactor and regulator of TRIP-Br1. Cell Signal. 2009; 21: 34-42. doi:10.1016/j.cellsig.2008.09.018
39. Cheong JK, Gunaratnam L, Zang ZZ, et al. TRIP-Br2 promotes oncogenesis in nude mice and is frequently overexpressed in multiple human tumors. J Transl Med. 2009; 7(8): 15. doi:10.1186/1479-5876-7-8
40. Chan CB, Liu X, Jang SW, et al. NGF inhibits human leukemia proliferation by downregulating cyclin A1 expression through promoting acinus/CtBP2 association. Oncogene. 2009; 28: 3825-3836. doi: 10.1038/onc.2009.236
41. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Cattran DC, Coppo R, Cook HT, et al. The Oxford classification of IgA nephropathy: rationale, clinic opathological correlations, and classification. Kidney Int. 2009; 76: 534-545. doi:10.1038/ki.2009.243
42. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Roberts IS, Cook HT, Troyanov S, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009; 76: 546-556. doi:10.1038/ki.2009.168.
43. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society. Coppo R, Troyanov S, Camilla R, et al. The Oxford IgA nephropathy clinic opathological classification is valid for children as well as adults. Kidney Int. 2010; 77: 921-927. doi:10.1038/ki.2010.43
44. Penney KL, Schumacher FR, Peter Kraft P, et al. Association of KLK3 (PSA) genetic variants with prostate cancer risk and PSA levels. Carcinogenesis. 2011; 32: 853-859. doi:10.1093/carcin/bgr050
45. Lewis NP, Treise D, Hsu SIH, Allen WL, Kang H. DTC genetic testing companies fail transparency prescriptions. New Gen and Soc. 2011; 30: 291-307. doi:10.1080/14636778.2011.600434
46. Liew CW, Boucher J, Cheong JK, et al. Ablation of TRIP-Br2, a regulator of fat lipolysis, thermogenesis and oxidative metabolism, prevents diet-induced obesity and insulin resistance. Nat Med. 2013; 19: 217-226. doi:10.1038/nm.3056
47. Cheong JK, Hsu SIH. Derailing UPS of protein turnover in cancer and other human diseases. J Cancer Res. 2013; 11. doi:10.1155/2013/167576
48. O Mara RJ, Hsu SIH, Wilson DR. Should MD-PhD scholars pursue graduate training in disciplines beyond conventional biomedical or clinical sciences?. Acad Med. 2014.